Nearly $1 Million in PPE Is Donated to International Medical Corps for COVID-19 Response Efforts

In Partnership with the Medtronic Foundation, More Than 400,000 KN95 Respirators and 1.1 Million Surgical Masks to be Distributed to Healthcare Facilities Across Continental U.S. and Puerto Rico

October 9, 2020

Nearly $1 Million in PPE was donated to the International Medical Corps for COVID-19 response efforts to support its ongoing COVID-19 response efforts in the continental United States and Puerto Rico. The donation was made by Medtronic.

PPE Donations includes more than 1.1 million surgical masks and 408,000 KN95 respirators, which are being distributed by International Medical Corps, a long-time partner of the Medtronic Foundation, to more than 15 hospitals and health facilities chosen for their locations in COVID-19 hot spots, or directly to individuals as part of prevention efforts. In addition, these facilities serve underserved and underinsured communities, most at-risk and most affected by this pandemic, particularly as COVID-19 rates are increasing in some key locations.

“When an emergency strikes, Medtronic and the Medtronic Foundation are among the first to be there, helping to ensure that first responders have the resources they need,” said Erica Tavares, vice president of Institutional Partnerships and Philanthropy at International Medical Corps. “With their donation, frontline health workers across the country will be able to safely provide healthcare to communities most in need.”

“Doctors, nurses, and other frontline healthcare workers continue to do heroic work despite the risks to their personal health and the ongoing challenge of maintaining an adequate supply of personal protective equipment,” said John Liddicoat, M.D., executive vice president and president of the Americas Region at Medtronic. “We recognize and appreciate their tireless efforts and we are proud to support them, together with the Medtronic Foundation, with this donation.”

 

SourceMedtronic

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”